Predicting lymph node metastasis in lung cancer
Prediction Model of Mediastinal Group IV Lymph Node Metastasis in Non-small Cell Lung Cancer Based on CT Radiomics
This study is testing a new way to use advanced CT scans to better predict if lung cancer has spread to certain lymph nodes in patients with non-small cell lung cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Sex | All |
| Sponsor | Qilu Hospital of Shandong University Academic / other |
| Locations | 1 site (Jinan, Shandong) |
| Trial ID | NCT06496360 on ClinicalTrials.gov |
What this trial studies
This study aims to improve the accuracy of diagnosing mediastinal lymph node metastasis in patients with non-small cell lung cancer (NSCLC) using advanced CT radiomics. It focuses on the critical lymph node stations 4 and 7, which are known hotspots for metastasis. By analyzing preoperative CT scans and correlating them with postoperative pathological findings, the study seeks to provide a more scientific basis for lymph node dissection strategies. The ultimate goal is to enhance individualized treatment plans and improve patient prognoses.
Who should consider this trial
Good fit: Ideal candidates for this study are patients undergoing surgical resection for NSCLC with confirmed pathological findings and complete clinical data.
Not a fit: Patients who have received preoperative chemoradiotherapy or have distant metastasis or other malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate staging and treatment plans for patients with NSCLC, potentially improving survival rates.
How similar studies have performed: While the use of CT radiomics in this context is promising, it is a relatively novel approach and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Surgical resection and systematic lymph node dissection were performed in the department of thoracic surgery, and the postoperative pathological findings were confirmed as NSCLC and complete pathological diagnostic data were retained. 2. Chest CT enhancement scan was completed within 2 weeks prior to surgery 3. Image quality meets analysis standards and clinical data is complete. 4. Lymph nodes that were pathologically confirmed to be metastatic or non-metastatic at station 4 were selected Exclusion Criteria: 1. Preoperative chemoradiotherapy or other treatment 2. Distant metastasis or other malignant tumors are present 3. Incomplete clinical data or image artifacts 4. No metastatic or non-metastatic lymph nodes were found at station 4
Where this trial is running
Jinan, Shandong
- Qilu Hospital of Shandong University — Jinan, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Yanru Kang, postgraduate
- Email: 2083884573@qq.com
- Phone: 18334864091
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.